Big Pharma, with eye on Anthropic, says AI is shrinking drug discovery timelines
Artificial intelligence has been speeding up early-stage drug development at major pharmaceutical companies, cutting the time needed to produce new molecules and bring them to the clinic by up to half, according to top scientists. Large pharmaceutical firms such as GSK, Bristol Myers Squibb, Novartis, Eli Lilly, Novo Nordisk, AstraZeneca, and Sanofi claim to have moved beyond less glamorous tasks for AI, like preparing regulatory filings, and now use the technology for designing molecules, selecting the most promising ones, and identifying safety risks.
AstraZeneca's Sharon Barr stated that AI is now used in every stage of the discovery and development pipeline. While AI companies like Anthropic are gearing up to be rivals, partners, or both, with a $1.5 trillion initial public offering, drug companies are unsure if these upstarts can succeed in tackling disease. Despite AI's potential, the number of AI-enabled drugs in clinical testing has only increased incrementally, with most programs still in early-stage development.
Written by urgent.news from CNA - Business's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
Other reports of this story
- Big Pharma, with eye on Anthropic, says AI is shrinking drug discovery timelines channelnewsasia.com